0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Fast-acting Human Insulin Market Research Report 2024
Published Date: August 2024
|
Report Code: QYRE-Auto-15W15759
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Fast acting Human Insulin Market Research Report 2023
BUY CHAPTERS

Global Fast-acting Human Insulin Market Research Report 2024

Code: QYRE-Auto-15W15759
Report
August 2024
Pages:91
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Fast-acting Human Insulin Market

The global Fast-acting Human Insulin market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Fast-acting Human Insulin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Fast-acting Human Insulin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Fast-acting Human Insulin include Sanofi, Geropharm, Wockhardt, Novo Nordisk, Eli Lilly and Company, Mannkind, Biocon, Julphar and ADOCIA, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Fast-acting Human Insulin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Fast-acting Human Insulin.

Report Scope

The Fast-acting Human Insulin market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Fast-acting Human Insulin market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Fast-acting Human Insulin manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Fast-acting Human Insulin Market Report

Report Metric Details
Report Name Fast-acting Human Insulin Market
Segment by Type
  • Lispro Insulin
  • Aspart Insulin
  • Glulisine Insulin
Segment by Application
  • Type 1 Diabetes
  • Type 2 Diabetes
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Sanofi, Geropharm, Wockhardt, Novo Nordisk, Eli Lilly and Company, Mannkind, Biocon, Julphar, ADOCIA, Tonghua Dongbao Pharmaceutical, Gan & Lee Pharmaceuticals, Zhejiang Hisun Pharmaceutical, Wuhan Biology Chemical Pharmacy
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Fast-acting Human Insulin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Fast-acting Human Insulin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Fast-acting Human Insulin Market report?

Ans: The main players in the Fast-acting Human Insulin Market are Sanofi, Geropharm, Wockhardt, Novo Nordisk, Eli Lilly and Company, Mannkind, Biocon, Julphar, ADOCIA, Tonghua Dongbao Pharmaceutical, Gan & Lee Pharmaceuticals, Zhejiang Hisun Pharmaceutical, Wuhan Biology Chemical Pharmacy

What are the Application segmentation covered in the Fast-acting Human Insulin Market report?

Ans: The Applications covered in the Fast-acting Human Insulin Market report are Type 1 Diabetes, Type 2 Diabetes

What are the Type segmentation covered in the Fast-acting Human Insulin Market report?

Ans: The Types covered in the Fast-acting Human Insulin Market report are Lispro Insulin, Aspart Insulin, Glulisine Insulin

1 Fast-acting Human Insulin Market Overview
1.1 Product Overview and Scope of Fast-acting Human Insulin
1.2 Fast-acting Human Insulin Segment by Type
1.2.1 Global Fast-acting Human Insulin Market Value Comparison by Type (2024-2030)
1.2.2 Lispro Insulin
1.2.3 Aspart Insulin
1.2.4 Glulisine Insulin
1.3 Fast-acting Human Insulin Segment by Application
1.3.1 Global Fast-acting Human Insulin Market Value by Application: (2024-2030)
1.3.2 Type 1 Diabetes
1.3.3 Type 2 Diabetes
1.4 Global Fast-acting Human Insulin Market Size Estimates and Forecasts
1.4.1 Global Fast-acting Human Insulin Revenue 2019-2030
1.4.2 Global Fast-acting Human Insulin Sales 2019-2030
1.4.3 Global Fast-acting Human Insulin Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Fast-acting Human Insulin Market Competition by Manufacturers
2.1 Global Fast-acting Human Insulin Sales Market Share by Manufacturers (2019-2024)
2.2 Global Fast-acting Human Insulin Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Fast-acting Human Insulin Average Price by Manufacturers (2019-2024)
2.4 Global Fast-acting Human Insulin Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Fast-acting Human Insulin, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Fast-acting Human Insulin, Product Type & Application
2.7 Fast-acting Human Insulin Market Competitive Situation and Trends
2.7.1 Fast-acting Human Insulin Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Fast-acting Human Insulin Players Market Share by Revenue
2.7.3 Global Fast-acting Human Insulin Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Fast-acting Human Insulin Retrospective Market Scenario by Region
3.1 Global Fast-acting Human Insulin Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Fast-acting Human Insulin Global Fast-acting Human Insulin Sales by Region: 2019-2030
3.2.1 Global Fast-acting Human Insulin Sales by Region: 2019-2024
3.2.2 Global Fast-acting Human Insulin Sales by Region: 2025-2030
3.3 Global Fast-acting Human Insulin Global Fast-acting Human Insulin Revenue by Region: 2019-2030
3.3.1 Global Fast-acting Human Insulin Revenue by Region: 2019-2024
3.3.2 Global Fast-acting Human Insulin Revenue by Region: 2025-2030
3.4 North America Fast-acting Human Insulin Market Facts & Figures by Country
3.4.1 North America Fast-acting Human Insulin Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Fast-acting Human Insulin Sales by Country (2019-2030)
3.4.3 North America Fast-acting Human Insulin Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Fast-acting Human Insulin Market Facts & Figures by Country
3.5.1 Europe Fast-acting Human Insulin Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Fast-acting Human Insulin Sales by Country (2019-2030)
3.5.3 Europe Fast-acting Human Insulin Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Fast-acting Human Insulin Market Facts & Figures by Country
3.6.1 Asia Pacific Fast-acting Human Insulin Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Fast-acting Human Insulin Sales by Country (2019-2030)
3.6.3 Asia Pacific Fast-acting Human Insulin Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Fast-acting Human Insulin Market Facts & Figures by Country
3.7.1 Latin America Fast-acting Human Insulin Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Fast-acting Human Insulin Sales by Country (2019-2030)
3.7.3 Latin America Fast-acting Human Insulin Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Fast-acting Human Insulin Market Facts & Figures by Country
3.8.1 Middle East and Africa Fast-acting Human Insulin Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Fast-acting Human Insulin Sales by Country (2019-2030)
3.8.3 Middle East and Africa Fast-acting Human Insulin Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Fast-acting Human Insulin Sales by Type (2019-2030)
4.1.1 Global Fast-acting Human Insulin Sales by Type (2019-2024)
4.1.2 Global Fast-acting Human Insulin Sales by Type (2025-2030)
4.1.3 Global Fast-acting Human Insulin Sales Market Share by Type (2019-2030)
4.2 Global Fast-acting Human Insulin Revenue by Type (2019-2030)
4.2.1 Global Fast-acting Human Insulin Revenue by Type (2019-2024)
4.2.2 Global Fast-acting Human Insulin Revenue by Type (2025-2030)
4.2.3 Global Fast-acting Human Insulin Revenue Market Share by Type (2019-2030)
4.3 Global Fast-acting Human Insulin Price by Type (2019-2030)
5 Segment by Application
5.1 Global Fast-acting Human Insulin Sales by Application (2019-2030)
5.1.1 Global Fast-acting Human Insulin Sales by Application (2019-2024)
5.1.2 Global Fast-acting Human Insulin Sales by Application (2025-2030)
5.1.3 Global Fast-acting Human Insulin Sales Market Share by Application (2019-2030)
5.2 Global Fast-acting Human Insulin Revenue by Application (2019-2030)
5.2.1 Global Fast-acting Human Insulin Revenue by Application (2019-2024)
5.2.2 Global Fast-acting Human Insulin Revenue by Application (2025-2030)
5.2.3 Global Fast-acting Human Insulin Revenue Market Share by Application (2019-2030)
5.3 Global Fast-acting Human Insulin Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Sanofi
6.1.1 Sanofi Corporation Information
6.1.2 Sanofi Description and Business Overview
6.1.3 Sanofi Fast-acting Human Insulin Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Sanofi Fast-acting Human Insulin Product Portfolio
6.1.5 Sanofi Recent Developments/Updates
6.2 Geropharm
6.2.1 Geropharm Corporation Information
6.2.2 Geropharm Description and Business Overview
6.2.3 Geropharm Fast-acting Human Insulin Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Geropharm Fast-acting Human Insulin Product Portfolio
6.2.5 Geropharm Recent Developments/Updates
6.3 Wockhardt
6.3.1 Wockhardt Corporation Information
6.3.2 Wockhardt Description and Business Overview
6.3.3 Wockhardt Fast-acting Human Insulin Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Wockhardt Fast-acting Human Insulin Product Portfolio
6.3.5 Wockhardt Recent Developments/Updates
6.4 Novo Nordisk
6.4.1 Novo Nordisk Corporation Information
6.4.2 Novo Nordisk Description and Business Overview
6.4.3 Novo Nordisk Fast-acting Human Insulin Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Novo Nordisk Fast-acting Human Insulin Product Portfolio
6.4.5 Novo Nordisk Recent Developments/Updates
6.5 Eli Lilly and Company
6.5.1 Eli Lilly and Company Corporation Information
6.5.2 Eli Lilly and Company Description and Business Overview
6.5.3 Eli Lilly and Company Fast-acting Human Insulin Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Eli Lilly and Company Fast-acting Human Insulin Product Portfolio
6.5.5 Eli Lilly and Company Recent Developments/Updates
6.6 Mannkind
6.6.1 Mannkind Corporation Information
6.6.2 Mannkind Description and Business Overview
6.6.3 Mannkind Fast-acting Human Insulin Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Mannkind Fast-acting Human Insulin Product Portfolio
6.6.5 Mannkind Recent Developments/Updates
6.7 Biocon
6.6.1 Biocon Corporation Information
6.6.2 Biocon Description and Business Overview
6.6.3 Biocon Fast-acting Human Insulin Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Biocon Fast-acting Human Insulin Product Portfolio
6.7.5 Biocon Recent Developments/Updates
6.8 Julphar
6.8.1 Julphar Corporation Information
6.8.2 Julphar Description and Business Overview
6.8.3 Julphar Fast-acting Human Insulin Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Julphar Fast-acting Human Insulin Product Portfolio
6.8.5 Julphar Recent Developments/Updates
6.9 ADOCIA
6.9.1 ADOCIA Corporation Information
6.9.2 ADOCIA Description and Business Overview
6.9.3 ADOCIA Fast-acting Human Insulin Sales, Revenue and Gross Margin (2019-2024)
6.9.4 ADOCIA Fast-acting Human Insulin Product Portfolio
6.9.5 ADOCIA Recent Developments/Updates
6.10 Tonghua Dongbao Pharmaceutical
6.10.1 Tonghua Dongbao Pharmaceutical Corporation Information
6.10.2 Tonghua Dongbao Pharmaceutical Description and Business Overview
6.10.3 Tonghua Dongbao Pharmaceutical Fast-acting Human Insulin Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Tonghua Dongbao Pharmaceutical Fast-acting Human Insulin Product Portfolio
6.10.5 Tonghua Dongbao Pharmaceutical Recent Developments/Updates
6.11 Gan & Lee Pharmaceuticals
6.11.1 Gan & Lee Pharmaceuticals Corporation Information
6.11.2 Gan & Lee Pharmaceuticals Fast-acting Human Insulin Description and Business Overview
6.11.3 Gan & Lee Pharmaceuticals Fast-acting Human Insulin Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Gan & Lee Pharmaceuticals Fast-acting Human Insulin Product Portfolio
6.11.5 Gan & Lee Pharmaceuticals Recent Developments/Updates
6.12 Zhejiang Hisun Pharmaceutical
6.12.1 Zhejiang Hisun Pharmaceutical Corporation Information
6.12.2 Zhejiang Hisun Pharmaceutical Fast-acting Human Insulin Description and Business Overview
6.12.3 Zhejiang Hisun Pharmaceutical Fast-acting Human Insulin Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Zhejiang Hisun Pharmaceutical Fast-acting Human Insulin Product Portfolio
6.12.5 Zhejiang Hisun Pharmaceutical Recent Developments/Updates
6.13 Wuhan Biology Chemical Pharmacy
6.13.1 Wuhan Biology Chemical Pharmacy Corporation Information
6.13.2 Wuhan Biology Chemical Pharmacy Fast-acting Human Insulin Description and Business Overview
6.13.3 Wuhan Biology Chemical Pharmacy Fast-acting Human Insulin Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Wuhan Biology Chemical Pharmacy Fast-acting Human Insulin Product Portfolio
6.13.5 Wuhan Biology Chemical Pharmacy Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Fast-acting Human Insulin Industry Chain Analysis
7.2 Fast-acting Human Insulin Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Fast-acting Human Insulin Production Mode & Process
7.4 Fast-acting Human Insulin Sales and Marketing
7.4.1 Fast-acting Human Insulin Sales Channels
7.4.2 Fast-acting Human Insulin Distributors
7.5 Fast-acting Human Insulin Customers
8 Fast-acting Human Insulin Market Dynamics
8.1 Fast-acting Human Insulin Industry Trends
8.2 Fast-acting Human Insulin Market Drivers
8.3 Fast-acting Human Insulin Market Challenges
8.4 Fast-acting Human Insulin Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
    Table 1. Global Fast-acting Human Insulin Market Value Comparison by Type (2024-2030) & (US$ Million)
    Table 2. Global Fast-acting Human Insulin Market Value Comparison by Application (2024-2030) & (US$ Million)
    Table 3. Global Fast-acting Human Insulin Market Competitive Situation by Manufacturers in 2023
    Table 4. Global Fast-acting Human Insulin Sales (K Units) of Key Manufacturers (2019-2024)
    Table 5. Global Fast-acting Human Insulin Sales Market Share by Manufacturers (2019-2024)
    Table 6. Global Fast-acting Human Insulin Revenue (US$ Million) by Manufacturers (2019-2024)
    Table 7. Global Fast-acting Human Insulin Revenue Share by Manufacturers (2019-2024)
    Table 8. Global Market Fast-acting Human Insulin Average Price (US$/Unit) of Key Manufacturers (2019-2024)
    Table 9. Global Key Players of Fast-acting Human Insulin, Industry Ranking, 2022 VS 2023 VS 2024
    Table 10. Global Key Manufacturers of Fast-acting Human Insulin, Manufacturing Sites & Headquarters
    Table 11. Global Key Manufacturers of Fast-acting Human Insulin, Product Type & Application
    Table 12. Global Key Manufacturers of Fast-acting Human Insulin, Date of Enter into This Industry
    Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Fast-acting Human Insulin by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Fast-acting Human Insulin as of 2023)
    Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 16. Global Fast-acting Human Insulin Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 17. Global Fast-acting Human Insulin Sales by Region (2019-2024) & (K Units)
    Table 18. Global Fast-acting Human Insulin Sales Market Share by Region (2019-2024)
    Table 19. Global Fast-acting Human Insulin Sales by Region (2025-2030) & (K Units)
    Table 20. Global Fast-acting Human Insulin Sales Market Share by Region (2025-2030)
    Table 21. Global Fast-acting Human Insulin Revenue by Region (2019-2024) & (US$ Million)
    Table 22. Global Fast-acting Human Insulin Revenue Market Share by Region (2019-2024)
    Table 23. Global Fast-acting Human Insulin Revenue by Region (2025-2030) & (US$ Million)
    Table 24. Global Fast-acting Human Insulin Revenue Market Share by Region (2025-2030)
    Table 25. North America Fast-acting Human Insulin Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 26. North America Fast-acting Human Insulin Sales by Country (2019-2024) & (K Units)
    Table 27. North America Fast-acting Human Insulin Sales by Country (2025-2030) & (K Units)
    Table 28. North America Fast-acting Human Insulin Revenue by Country (2019-2024) & (US$ Million)
    Table 29. North America Fast-acting Human Insulin Revenue by Country (2025-2030) & (US$ Million)
    Table 30. Europe Fast-acting Human Insulin Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 31. Europe Fast-acting Human Insulin Sales by Country (2019-2024) & (K Units)
    Table 32. Europe Fast-acting Human Insulin Sales by Country (2025-2030) & (K Units)
    Table 33. Europe Fast-acting Human Insulin Revenue by Country (2019-2024) & (US$ Million)
    Table 34. Europe Fast-acting Human Insulin Revenue by Country (2025-2030) & (US$ Million)
    Table 35. Asia Pacific Fast-acting Human Insulin Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 36. Asia Pacific Fast-acting Human Insulin Sales by Region (2019-2024) & (K Units)
    Table 37. Asia Pacific Fast-acting Human Insulin Sales by Region (2025-2030) & (K Units)
    Table 38. Asia Pacific Fast-acting Human Insulin Revenue by Region (2019-2024) & (US$ Million)
    Table 39. Asia Pacific Fast-acting Human Insulin Revenue by Region (2025-2030) & (US$ Million)
    Table 40. Latin America Fast-acting Human Insulin Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Latin America Fast-acting Human Insulin Sales by Country (2019-2024) & (K Units)
    Table 42. Latin America Fast-acting Human Insulin Sales by Country (2025-2030) & (K Units)
    Table 43. Latin America Fast-acting Human Insulin Revenue by Country (2019-2024) & (US$ Million)
    Table 44. Latin America Fast-acting Human Insulin Revenue by Country (2025-2030) & (US$ Million)
    Table 45. Middle East & Africa Fast-acting Human Insulin Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 46. Middle East & Africa Fast-acting Human Insulin Sales by Country (2019-2024) & (K Units)
    Table 47. Middle East & Africa Fast-acting Human Insulin Sales by Country (2025-2030) & (K Units)
    Table 48. Middle East & Africa Fast-acting Human Insulin Revenue by Country (2019-2024) & (US$ Million)
    Table 49. Middle East & Africa Fast-acting Human Insulin Revenue by Country (2025-2030) & (US$ Million)
    Table 50. Global Fast-acting Human Insulin Sales (K Units) by Type (2019-2024)
    Table 51. Global Fast-acting Human Insulin Sales (K Units) by Type (2025-2030)
    Table 52. Global Fast-acting Human Insulin Sales Market Share by Type (2019-2024)
    Table 53. Global Fast-acting Human Insulin Sales Market Share by Type (2025-2030)
    Table 54. Global Fast-acting Human Insulin Revenue (US$ Million) by Type (2019-2024)
    Table 55. Global Fast-acting Human Insulin Revenue (US$ Million) by Type (2025-2030)
    Table 56. Global Fast-acting Human Insulin Revenue Market Share by Type (2019-2024)
    Table 57. Global Fast-acting Human Insulin Revenue Market Share by Type (2025-2030)
    Table 58. Global Fast-acting Human Insulin Price (US$/Unit) by Type (2019-2024)
    Table 59. Global Fast-acting Human Insulin Price (US$/Unit) by Type (2025-2030)
    Table 60. Global Fast-acting Human Insulin Sales (K Units) by Application (2019-2024)
    Table 61. Global Fast-acting Human Insulin Sales (K Units) by Application (2025-2030)
    Table 62. Global Fast-acting Human Insulin Sales Market Share by Application (2019-2024)
    Table 63. Global Fast-acting Human Insulin Sales Market Share by Application (2025-2030)
    Table 64. Global Fast-acting Human Insulin Revenue (US$ Million) by Application (2019-2024)
    Table 65. Global Fast-acting Human Insulin Revenue (US$ Million) by Application (2025-2030)
    Table 66. Global Fast-acting Human Insulin Revenue Market Share by Application (2019-2024)
    Table 67. Global Fast-acting Human Insulin Revenue Market Share by Application (2025-2030)
    Table 68. Global Fast-acting Human Insulin Price (US$/Unit) by Application (2019-2024)
    Table 69. Global Fast-acting Human Insulin Price (US$/Unit) by Application (2025-2030)
    Table 70. Sanofi Corporation Information
    Table 71. Sanofi Description and Business Overview
    Table 72. Sanofi Fast-acting Human Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 73. Sanofi Fast-acting Human Insulin Product
    Table 74. Sanofi Recent Developments/Updates
    Table 75. Geropharm Corporation Information
    Table 76. Geropharm Description and Business Overview
    Table 77. Geropharm Fast-acting Human Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 78. Geropharm Fast-acting Human Insulin Product
    Table 79. Geropharm Recent Developments/Updates
    Table 80. Wockhardt Corporation Information
    Table 81. Wockhardt Description and Business Overview
    Table 82. Wockhardt Fast-acting Human Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 83. Wockhardt Fast-acting Human Insulin Product
    Table 84. Wockhardt Recent Developments/Updates
    Table 85. Novo Nordisk Corporation Information
    Table 86. Novo Nordisk Description and Business Overview
    Table 87. Novo Nordisk Fast-acting Human Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 88. Novo Nordisk Fast-acting Human Insulin Product
    Table 89. Novo Nordisk Recent Developments/Updates
    Table 90. Eli Lilly and Company Corporation Information
    Table 91. Eli Lilly and Company Description and Business Overview
    Table 92. Eli Lilly and Company Fast-acting Human Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 93. Eli Lilly and Company Fast-acting Human Insulin Product
    Table 94. Eli Lilly and Company Recent Developments/Updates
    Table 95. Mannkind Corporation Information
    Table 96. Mannkind Description and Business Overview
    Table 97. Mannkind Fast-acting Human Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 98. Mannkind Fast-acting Human Insulin Product
    Table 99. Mannkind Recent Developments/Updates
    Table 100. Biocon Corporation Information
    Table 101. Biocon Description and Business Overview
    Table 102. Biocon Fast-acting Human Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 103. Biocon Fast-acting Human Insulin Product
    Table 104. Biocon Recent Developments/Updates
    Table 105. Julphar Corporation Information
    Table 106. Julphar Description and Business Overview
    Table 107. Julphar Fast-acting Human Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 108. Julphar Fast-acting Human Insulin Product
    Table 109. Julphar Recent Developments/Updates
    Table 110. ADOCIA Corporation Information
    Table 111. ADOCIA Description and Business Overview
    Table 112. ADOCIA Fast-acting Human Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 113. ADOCIA Fast-acting Human Insulin Product
    Table 114. ADOCIA Recent Developments/Updates
    Table 115. Tonghua Dongbao Pharmaceutical Corporation Information
    Table 116. Tonghua Dongbao Pharmaceutical Description and Business Overview
    Table 117. Tonghua Dongbao Pharmaceutical Fast-acting Human Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 118. Tonghua Dongbao Pharmaceutical Fast-acting Human Insulin Product
    Table 119. Tonghua Dongbao Pharmaceutical Recent Developments/Updates
    Table 120. Gan & Lee Pharmaceuticals Corporation Information
    Table 121. Gan & Lee Pharmaceuticals Description and Business Overview
    Table 122. Gan & Lee Pharmaceuticals Fast-acting Human Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 123. Gan & Lee Pharmaceuticals Fast-acting Human Insulin Product
    Table 124. Gan & Lee Pharmaceuticals Recent Developments/Updates
    Table 125. Zhejiang Hisun Pharmaceutical Corporation Information
    Table 126. Zhejiang Hisun Pharmaceutical Description and Business Overview
    Table 127. Zhejiang Hisun Pharmaceutical Fast-acting Human Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 128. Zhejiang Hisun Pharmaceutical Fast-acting Human Insulin Product
    Table 129. Zhejiang Hisun Pharmaceutical Recent Developments/Updates
    Table 130. Wuhan Biology Chemical Pharmacy Corporation Information
    Table 131. Wuhan Biology Chemical Pharmacy Description and Business Overview
    Table 132. Wuhan Biology Chemical Pharmacy Fast-acting Human Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 133. Wuhan Biology Chemical Pharmacy Fast-acting Human Insulin Product
    Table 134. Wuhan Biology Chemical Pharmacy Recent Developments/Updates
    Table 135. Key Raw Materials Lists
    Table 136. Raw Materials Key Suppliers Lists
    Table 137. Fast-acting Human Insulin Distributors List
    Table 138. Fast-acting Human Insulin Customers List
    Table 139. Fast-acting Human Insulin Market Trends
    Table 140. Fast-acting Human Insulin Market Drivers
    Table 141. Fast-acting Human Insulin Market Challenges
    Table 142. Fast-acting Human Insulin Market Restraints
    Table 143. Research Programs/Design for This Report
    Table 144. Key Data Information from Secondary Sources
    Table 145. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of Fast-acting Human Insulin
    Figure 2. Global Fast-acting Human Insulin Market Value Comparison by Type (2024-2030) & (US$ Million)
    Figure 3. Global Fast-acting Human Insulin Market Share by Type in 2023 & 2030
    Figure 4. Lispro Insulin Product Picture
    Figure 5. Aspart Insulin Product Picture
    Figure 6. Glulisine Insulin Product Picture
    Figure 7. Global Fast-acting Human Insulin Market Value Comparison by Application (2024-2030) & (US$ Million)
    Figure 8. Global Fast-acting Human Insulin Market Share by Application in 2023 & 2030
    Figure 9. Type 1 Diabetes
    Figure 10. Type 2 Diabetes
    Figure 11. Global Fast-acting Human Insulin Revenue, (US$ Million), 2019 VS 2023 VS 2030
    Figure 12. Global Fast-acting Human Insulin Market Size (2019-2030) & (US$ Million)
    Figure 13. Global Fast-acting Human Insulin Sales (2019-2030) & (K Units)
    Figure 14. Global Fast-acting Human Insulin Average Price (US$/Unit) & (2019-2030)
    Figure 15. Fast-acting Human Insulin Report Years Considered
    Figure 16. Fast-acting Human Insulin Sales Share by Manufacturers in 2023
    Figure 17. Global Fast-acting Human Insulin Revenue Share by Manufacturers in 2023
    Figure 18. The Global 5 and 10 Largest Fast-acting Human Insulin Players: Market Share by Revenue in 2023
    Figure 19. Fast-acting Human Insulin Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
    Figure 20. Global Fast-acting Human Insulin Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Figure 21. North America Fast-acting Human Insulin Sales Market Share by Country (2019-2030)
    Figure 22. North America Fast-acting Human Insulin Revenue Market Share by Country (2019-2030)
    Figure 23. United States Fast-acting Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 24. Canada Fast-acting Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 25. Europe Fast-acting Human Insulin Sales Market Share by Country (2019-2030)
    Figure 26. Europe Fast-acting Human Insulin Revenue Market Share by Country (2019-2030)
    Figure 27. Germany Fast-acting Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 28. France Fast-acting Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 29. U.K. Fast-acting Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 30. Italy Fast-acting Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 31. Russia Fast-acting Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 32. Asia Pacific Fast-acting Human Insulin Sales Market Share by Region (2019-2030)
    Figure 33. Asia Pacific Fast-acting Human Insulin Revenue Market Share by Region (2019-2030)
    Figure 34. China Fast-acting Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 35. Japan Fast-acting Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 36. South Korea Fast-acting Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 37. India Fast-acting Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 38. Australia Fast-acting Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 39. China Taiwan Fast-acting Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 40. Southeast Asia Fast-acting Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 41. Latin America Fast-acting Human Insulin Sales Market Share by Country (2019-2030)
    Figure 42. Latin America Fast-acting Human Insulin Revenue Market Share by Country (2019-2030)
    Figure 43. Mexico Fast-acting Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 44. Brazil Fast-acting Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 45. Argentina Fast-acting Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 46. Middle East & Africa Fast-acting Human Insulin Sales Market Share by Country (2019-2030)
    Figure 47. Middle East & Africa Fast-acting Human Insulin Revenue Market Share by Country (2019-2030)
    Figure 48. Turkey Fast-acting Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 49. Saudi Arabia Fast-acting Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 50. UAE Fast-acting Human Insulin Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 51. Global Sales Market Share of Fast-acting Human Insulin by Type (2019-2030)
    Figure 52. Global Revenue Market Share of Fast-acting Human Insulin by Type (2019-2030)
    Figure 53. Global Fast-acting Human Insulin Price (US$/Unit) by Type (2019-2030)
    Figure 54. Global Sales Market Share of Fast-acting Human Insulin by Application (2019-2030)
    Figure 55. Global Revenue Market Share of Fast-acting Human Insulin by Application (2019-2030)
    Figure 56. Global Fast-acting Human Insulin Price (US$/Unit) by Application (2019-2030)
    Figure 57. Fast-acting Human Insulin Value Chain
    Figure 58. Fast-acting Human Insulin Production Process
    Figure 59. Channels of Distribution (Direct Vs Distribution)
    Figure 60. Distributors Profiles
    Figure 61. Bottom-up and Top-down Approaches for This Report
    Figure 62. Data Triangulation
    Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS